Clinical Trial Detail

NCT ID NCT02779751
Title A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Eli Lilly and Company

Her2-receptor negative breast cancer

lung non-small cell carcinoma


Abemaciclib + Pembrolizumab

Age Groups: senior adult

Additional content available in CKB BOOST